A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system
- PMID: 22279180
- PMCID: PMC3299416
- DOI: 10.1093/jac/dkr566
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system
Abstract
Fluoroquinolone resistance in Mycobacterium tuberculosis has become increasingly important. A review of mutations in DNA gyrase, the fluoroquinolone target, is needed to improve the molecular detection of resistance. We performed a systematic review of studies reporting mutations in DNA gyrase genes in clinical M. tuberculosis isolates. From 42 studies that met inclusion criteria, 1220 fluoroquinolone-resistant M. tuberculosis isolates underwent sequencing of the quinolone resistance-determining region (QRDR) of gyrA; 780 (64%) had mutations. The QRDR of gyrB was sequenced in 534 resistant isolates; 17 (3%) had mutations. Mutations at gyrA codons 90, 91 or 94 were present in 654/1220 (54%) resistant isolates. Four different GyrB numbering systems were reported, resulting in mutation location discrepancies. We propose a consensus numbering system. Most fluoroquinolone-resistant M. tuberculosis isolates had mutations in DNA gyrase, but a substantial proportion did not. The proposed consensus numbering system can improve molecular detection of resistance and identification of novel mutations.
Similar articles
-
High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility.J Clin Microbiol. 2012 Apr;50(4):1390-6. doi: 10.1128/JCM.05286-11. Epub 2011 Dec 21. J Clin Microbiol. 2012. PMID: 22189117 Free PMC article.
-
Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.J Antibiot (Tokyo). 2015 Jan;68(1):63-6. doi: 10.1038/ja.2014.95. Epub 2014 Jul 23. J Antibiot (Tokyo). 2015. PMID: 25052485
-
Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China.Diagn Microbiol Infect Dis. 2012 Jul;73(3):260-3. doi: 10.1016/j.diagmicrobio.2012.03.025. Epub 2012 May 4. Diagn Microbiol Infect Dis. 2012. PMID: 22560167
-
Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review.PLoS One. 2015 Mar 27;10(3):e0120470. doi: 10.1371/journal.pone.0120470. eCollection 2015. PLoS One. 2015. PMID: 25816236 Free PMC article. Review.
-
Mechanisms of fluoroquinolone resistance in Mycobacterium tuberculosis.Yi Chuan. 2016 Oct 20;38(10):918-927. doi: 10.16288/j.yczz.16-136. Yi Chuan. 2016. PMID: 27806933 Review.
Cited by
-
Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach.Nat Commun. 2024 Jan 12;15(1):488. doi: 10.1038/s41467-023-44325-5. Nat Commun. 2024. PMID: 38216576 Free PMC article.
-
Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach.Res Sq [Preprint]. 2023 Oct 2:rs.3.rs-3378915. doi: 10.21203/rs.3.rs-3378915/v1. Res Sq. 2023. PMID: 37886522 Free PMC article. Updated. Preprint.
-
Amino acid 17 in QRDR of Gyrase A plays a key role in fluoroquinolones susceptibility in mycobacteria.Microbiol Spectr. 2023 Dec 12;11(6):e0280923. doi: 10.1128/spectrum.02809-23. Epub 2023 Oct 13. Microbiol Spectr. 2023. PMID: 37831477 Free PMC article.
-
Menthol- and thymol-based ciprofloxacin derivatives against Mycobacterium tuberculosis: in vitro activity, lipophilicity, and computational studies.Sci Rep. 2023 Sep 28;13(1):16328. doi: 10.1038/s41598-023-43708-4. Sci Rep. 2023. PMID: 37770610 Free PMC article.
-
Genomic Analysis of Mycobacterium tuberculosis Strains Resistant to Second-Line Anti-Tuberculosis Drugs in Lusaka, Zambia.Antibiotics (Basel). 2023 Jun 29;12(7):1126. doi: 10.3390/antibiotics12071126. Antibiotics (Basel). 2023. PMID: 37508222 Free PMC article.
References
-
- American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52:1–77. - PubMed
-
- Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393:537–44. - PubMed
-
- Mdluli K, Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007;7:159–68. - PubMed
-
- Hooper D, Rubinstein E. Quinolone Antimicrobial Agents. Washington, DC: ASM Press; 2008.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
